Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth

The worldwide frequency of head and neck squamous cell carcinoma (HNSCC) is approximately 800,000 new cases, with 430,000 deaths annually. We determined that LZK (encoded by MAP3K13) is a therapeutic target in HNSCC and showed that inhibition with small molecule inhibitors decreases the viability of HNSCC cells with amplified MAP3K13. A drug-resistant mutant of LZK blocks decreases in cell viability due to LZK inhibition, indicating on-target activity by two separate small molecules. Inhibition of LZK catalytic activity suppressed tumor growth in HNSCC PDX models with amplified MAP3K13. We found that the kinase activity of LZK stabilized c-MYC and that LZK stabilized gain-of-function (GOF) p53 through a kinase-independent mechanism. Therefore, we designed proteolysis-targeting chimeras (PROTACs) and demonstrate that our lead PROTAC promotes LZK degradation and suppresses expression of GOF p53 and c-MYC leading to impaired viability of HNSCC cell lines. This research provides a strong basis for development of therapeutics targeting LZK in HNSCCs with amplification of the gene. One Sentence Summary This study establishes the kinase LZK as a therapeutic target for HNSCC through regulation of c-MYC expression.

• Publication year

  2024

• Venue

  bioRxiv

• Publication date

  2024-11-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/2024.11.19.623840PMID 39605563PMCID 11601640
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncogene-like addiction to aneuploidy in human cancers

  2023cited by this paper
• Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

  2022cited by this paper
• TNIK is a therapeutic target in Lung Squamous Cell Carcinoma and regulates FAK activation through Merlin.

  2021cited by this paper
• The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences

  2021cited by this paper
• Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date

  2020cited by this paper
• Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

  2020cited by this paper
• Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

  2020cited by this paper
• MYC Oncogene Contributions to Release of Cell Cycle Brakes

  2019cited by this paper
• Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.

  2019cited by this paper
• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

  2019cited by this paper
• Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer

  2019cited by this paper
• The MAP3K13-TRIM25-FBXW7α axis affects c-Myc protein stability and tumor development

  2019cited by this paper
• Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers

  2018cited by this paper
• Highly predictive and interpretable models for PAMPA permeability.

  2017cited by this paper
• Survival of Head and Neck Cancer Cells Relies upon LZK Kinase-Mediated Stabilization of Mutant p53.

  2017cited by this paper
• Endogenous Replication Stress in Mother Cells Leads to Quiescence of Daughter Cells.

  2017cited by this paper
• Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

  2017cited by this paper
• Small-Molecule PROTACS: New Approaches to Protein Degradation.

  2016cited by this paper
• The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition

  2016cited by this paper
• Induced protein degradation: an emerging drug discovery paradigm

  2016cited by this paper
• The MaxQuant computational platform for mass spectrometry-based shotgun proteomics

  2016cited by this paper
• CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing

  2016cited by this paper
• The Perseus computational platform for comprehensive analysis of (prote)omics data

  2016cited by this paper
• An Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software

  2016cited by this paper
• Irreversible APC(Cdh1) Inactivation Underlies the Point of No Return for Cell-Cycle Entry.

  2016cited by this paper
• Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models.

  2015cited by this paper
• The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers

  2015cited by this paper
• Comprehensive genomic characterization of head and neck squamous cell carcinomas

  2015cited by this paper
• The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma.

  2014cited by this paper
• Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

  2014cited by this paper
• p53 mutations in cancer

  2013cited by this paper
• New targetable oncogenes in non-small-cell lung cancer.

  2013cited by this paper
• The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit.

  2013cited by this paper
• RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

  2011cited by this paper
• Mutant p53 gain-of-function in cancer.

  2010cited by this paper
• Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma

  2010cited by this paper
• MYC gene amplification reveals clinical association with head and neck squamous cell carcinoma in Indian patients.

  2009cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Mixed lineage kinase LZK forms a functional signaling complex with JIP-1, a scaffold protein of the c-Jun NH(2)-terminal kinase pathway.

  2001cited by this paper
• Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification.

  2001cited by this paper

• No citing papers are available for this paper.